Australian Clinical Labs (ASX:ACL) - 주가, 뉴스 및 분석

ACL 주식 개요

Australian Clinical Labs Limited는 호주에서 병리 진단 서비스를 제공합니다. 자세한 내용

ACL 기본 분석
눈송이 점수
가치 평가	3/6
미래 성장	3/6
과거 실적	1/6
재무 상태	4/6
배당금	2/6

보상

공정 가치 추정치보다 낮은 41.7% 에서 거래

수익은 매년 15.98% 증가할 것으로 예상됩니다.

위험 분석

재무 결과에 영향을 미치는 대규모 일회성 항목

3.46% 의 배당금은 수익으로 잘 충당되지 않습니다.

이익 마진 (3.4%) 작년보다 낮습니다 (5.2%)

Australian Clinical Labs Limited 경쟁사

Healthia

ASX:HLA

AU$252.1m

SILK Laser Australia

ASX:SLA

AU$177.4m

Apiam Animal Health

ASX:AHX

AU$84.0m

Sonic Healthcare

ASX:SHL

AU$13.3b

가격 내역 및 성능

다음에 대한 모든 사상 최고가, 변동 및 가격 하락 요약 Australian Clinical Labs
과거 주가
현재 주가	AU$3.47
52주 최고치	AU$3.86
52주 최저치	AU$2.14
베타	1.15
11개월 변경	-3.88%
3개월 변경 사항	22.61%
1년 변경 사항	35.55%
33년 변화	-17.97%
5년 변화	n/a
IPO 이후 변화	1.46%

최근 뉴스 및 업데이트

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Sep 03

Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?

Sep 02

Recent updates

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Sep 03

Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

Aug 14

Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Feb 25

New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

Dec 22

The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

Dec 21

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Sep 01

주주 수익률

	ACL	AU Healthcare	AU 마켓
7D	-2.0%	0.7%	1.5%
1Y	35.5%	4.0%	17.2%

수익률 대 산업: ACL 지난 1년 동안 4 %를 반환한 Australian Healthcare 산업을 초과했습니다.

수익률 대 시장: ACL 지난 1년 동안 17.2 %를 반환한 Australian 시장을 초과했습니다.

가격 변동성

Is ACL's price volatile compared to industry and market?
ACL volatility
ACL Average Weekly Movement	5.0%
Healthcare Industry Average Movement	5.1%
Market Average Movement	8.6%
10% most volatile stocks in AU Market	17.3%
10% least volatile stocks in AU Market	3.4%

안정적인 주가: ACL 는) 지난 3개월 동안 큰 가격 변동성이 없었습니다.

시간에 따른 변동성: ACL 의 주간 변동성( 5% )은 지난 1년 동안 안정적인 모습을 보였습니다.

회사 소개

설립	직원	CEO	웹사이트
2020	4,900	Melinda McGrath	www.clinicallabs.com.au

Australian Clinical Labs Limited는 호주에서 병리 진단 서비스를 제공합니다. 이 회사는 일상적인 병리 검사, 고급 분자유전학 검사, 하모니 NIPT 및 임신 초기 검사, 유전자 보균자 검사, 화학 병리, 조직 병리 및 세포 병리, 혈액학, 알레르기 및 면역학, 혈청학 및 미생물학, 감염성 분자 검사, 심장 검사 서비스, 기능 병리, 수의 병리, 상용 약물 및 알코올 검사 서비스 등 다양한 서비스를 제공합니다. 이 회사는 개인 및 공공 병원에 서비스를 제공합니다.

Australian Clinical Labs Limited 기본 사항 요약

Australian Clinical Labs 의 수익과 매출은 시가총액과 어떻게 비교하나요?
ACL 기본 통계
시가총액	AU$682.41m
수익(TTM)	AU$23.93m
수익(TTM)	AU$696.37m

28.9x

P/E 비율

1.0x

P/S 비율

ACL 주가가 과대평가되어 있나요?

공정 가치 및 가치 분석 보기

수익 및 수익

최신 수익 보고서의 주요 수익성 통계(TTM)
ACL 손익 계산서(TTM)
수익	AU$696.37m
수익 비용	AU$442.37m
총 이익	AU$254.00m
기타 비용	AU$230.07m
수익	AU$23.93m

최근 보고된 수익

Jun 30, 2024

다음 수익 날짜

Feb 26, 2025

주당 순이익(EPS)	0.12
총 마진	36.48%
순이익 마진	3.44%
부채/자본 비율	31.0%

ACL 의 장기적인 성과는 어땠나요?

과거 실적 및 비교 보기

배당금

3.5%

현재 배당 수익률

100%

지급 비율

ACL 주식 개요

보상

위험 분석

Australian Clinical Labs Limited 경쟁사

ASX:HLA

AU$252.1m

ASX:SLA

AU$177.4m

ASX:AHX

AU$84.0m

ASX:SHL

AU$13.3b

가격 내역 및 성능

최근 뉴스 및 업데이트

Australian Clinical Labs Limited to Report Fiscal Year 2025 Results on Aug 26, 2025

Investor sentiment improves as stock rises 25%

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?

Final dividend of AU$0.09 announced

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Recent updates

Australian Clinical Labs Limited to Report Fiscal Year 2025 Results on Aug 26, 2025

Investor sentiment improves as stock rises 25%

Why Investors Shouldn't Be Surprised By Australian Clinical Labs Limited's (ASX:ACL) 29% Share Price Surge

Should You Think About Buying Australian Clinical Labs Limited (ASX:ACL) Now?

Final dividend of AU$0.09 announced

Full year 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Australian Clinical Labs Limited Provides Financial Guidance for the Fiscal Year 2025

Australian Clinical Labs Limited to Report Fiscal Year 2024 Results on Aug 29, 2024

Australian Clinical Labs Limited, Annual General Meeting, Oct 25, 2024

We Think Australian Clinical Labs (ASX:ACL) Is Taking Some Risk With Its Debt

Upcoming dividend of AU$0.03 per share

Consensus EPS estimates fall by 20%

First half dividend reduced to AU$0.03

First half 2024 earnings released: EPS: AU$0.025 (vs AU$0.13 in 1H 2023)

Are Investors Undervaluing Australian Clinical Labs Limited (ASX:ACL) By 46%?

Australian Clinical Labs Limited to Report First Half, 2024 Results on Feb 28, 2024

Is It Time To Consider Buying Australian Clinical Labs Limited (ASX:ACL)?

Price target decreased by 7.5% to AU$3.56

Upcoming dividend of AU$0.07 per share at 4.6% yield

Consensus EPS estimates fall by 21%

Australian Clinical Labs Limited Announces Appointment of Christine Bartlett as Non-Executive Director

Australian Clinical Labs Limited Declares Full Year Fully Franked Dividend for the Fiscal Year 2023, Payable on 3 October 2023

Full year 2023 earnings: EPS and revenues miss analyst expectations

Upcoming dividend of AU$0.07 per share at 13% yield

Price target increased by 7.1% to AU$4.03

First half 2023 earnings released: EPS: AU$0.13 (vs AU$0.65 in 1H 2022)

Australian Clinical Labs Limited Announces Dividend for the Six Months Ended December 31, 2022, Payable on April 26, 2023

Investor sentiment improves as stock rises 16%

Price target decreased by 8.5% to AU$3.76

Price target decreased to AU$4.27

High number of new and inexperienced directors

Price target decreased to AU$4.62

Independent Non-Executive Director recently sold AU$71k worth of stock

Australian Clinical Labs Limited Announces Resignation of Dr. Michael Stanford as Non-Executive Director

Australian Clinical Labs Limited, Annual General Meeting, Oct 25, 2023

Independent Non-Executive Director recently sold AU$140k worth of stock

Upcoming dividend of AU$0.41 per share

Here's Why We Think Australian Clinical Labs (ASX:ACL) Might Deserve Your Attention Today

Full year 2022 earnings: EPS misses analyst expectations

Price target decreased to AU$5.30

Australian Clinical Labs Limited Declares Dividend for the Period of Six Months Ended 30 June 2022

Investor sentiment deteriorated over the past week

CEO & Executive Director recently bought AU$335k worth of stock

High number of new and inexperienced directors

First half 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Australian Clinical Labs Limited Declares Ordinary Dividend for the Period of Six Months December 31, 2021, Payable April 21, 2022

Australian Clinical Labs Limited (ASX:ACL) Just Reported Half-Year Earnings: Have Analysts Changed Their Mind On The Stock?

Australian Clinical Labs Limited Revises Earnings Guidance for the First Half 2022

New Forecasts: Here's What Analysts Think The Future Holds For Australian Clinical Labs Limited (ASX:ACL)

The Market Lifts Australian Clinical Labs Limited (ASX:ACL) Shares 31% But It Can Do More

Investor sentiment improved over the past week

Consensus EPS estimates increase by 46%

Australian Clinical Labs Limited (ASX:ACL) completed the acquisition of Medlab Pathology Pty Ltd.

Independent Non-Executive Director recently bought AU$99k worth of stock

The Strong Earnings Posted By Australian Clinical Labs (ASX:ACL) Are A Good Indication Of The Strength Of The Business

Full year 2021 earnings released: EPS AU$0.40 (vs AU$0.28 in FY 2020)

Australian Clinical Labs Limited Provides Earnings Guidance for the Fiscal Year of 2021

Australian Clinical Labs Limited has completed an IPO in the amount of AUD 408.559209 million.

주주 수익률